Global Hematologic Malignancies Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Hematologic Malignancies Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Leukemia
  • 1.4.3 Lymphoma
  • 1.4.4 Multiple Myeloma
  • 1.4.5 Others
• 1.5 Market by Application
  • 1.5.1 Global Hematologic Malignancies Market Share by Application (2014-2025)
  • 1.5.2 Chemotherapy
  • 1.5.3 Radiotherapy
  • 1.5.4 Immunotherapy
  • 1.5.5 Stem Cell Transplantation
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Hematologic Malignancies Market Size
• 2.2 Hematologic Malignancies Growth Trends by Regions
  • 2.2.1 Hematologic Malignancies Market Size by Regions (2014-2025)
  • 2.2.2 Hematologic Malignancies Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Hematologic Malignancies Market Size by Manufacturers
  • 3.1.1 Global Hematologic Malignancies Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Hematologic Malignancies Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
• 3.2 Hematologic Malignancies Key Players Head office and Area Served
• 3.3 Key Players Hematologic Malignancies Product/Solution/Service
• 3.4 Date of Enter into Hematologic Malignancies Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Hematologic Malignancies Market Size by Type (2014-2019)
• 4.2 Global Hematologic Malignancies Market Size by Application (2014-2019)

5 United States

• 5.1 United States Hematologic Malignancies Market Size (2014-2019)
• 5.2 Hematologic Malignancies Key Players in United States
• 5.3 United States Hematologic Malignancies Market Size by Type
• 5.4 United States Hematologic Malignancies Market Size by Application

6 Europe

• 6.1 Europe Hematologic Malignancies Market Size (2014-2019)
• 6.2 Hematologic Malignancies Key Players in Europe
• 6.3 Europe Hematologic Malignancies Market Size by Type
• 6.4 Europe Hematologic Malignancies Market Size by Application

7 China

• 7.1 China Hematologic Malignancies Market Size (2014-2019)
• 7.2 Hematologic Malignancies Key Players in China
• 7.3 China Hematologic Malignancies Market Size by Type
• 7.4 China Hematologic Malignancies Market Size by Application

8 Japan

• 8.1 Japan Hematologic Malignancies Market Size (2014-2019)
• 8.2 Hematologic Malignancies Key Players in Japan
• 8.3 Japan Hematologic Malignancies Market Size by Type
• 8.4 Japan Hematologic Malignancies Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Hematologic Malignancies Market Size (2014-2019)
• 9.2 Hematologic Malignancies Key Players in Southeast Asia
• 9.3 Southeast Asia Hematologic Malignancies Market Size by Type
• 9.4 Southeast Asia Hematologic Malignancies Market Size by Application

10 India

• 10.1 India Hematologic Malignancies Market Size (2014-2019)
• 10.2 Hematologic Malignancies Key Players in India
• 10.3 India Hematologic Malignancies Market Size by Type
• 10.4 India Hematologic Malignancies Market Size by Application

11 Central & South America

• 11.1 Central & South America Hematologic Malignancies Market Size (2014-2019)
• 11.2 Hematologic Malignancies Key Players in Central & South America
• 11.3 Central & South America Hematologic Malignancies Market Size by Type
• 11.4 Central & South America Hematologic Malignancies Market Size by Application

12 International Players Profiles

• 12.1 Pfizer, Inc.
  • 12.1.1 Pfizer, Inc. Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Hematologic Malignancies Introduction
  • 12.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.1.5 Pfizer, Inc. Recent Development
• 12.2 F. Hoffmann-LA Roche ltd
  • 12.2.1 F. Hoffmann-LA Roche ltd Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Hematologic Malignancies Introduction
  • 12.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.2.5 F. Hoffmann-LA Roche ltd Recent Development
• 12.3 Sanofi-Aventis
  • 12.3.1 Sanofi-Aventis Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Hematologic Malignancies Introduction
  • 12.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.3.5 Sanofi-Aventis Recent Development
• 12.4 Bristol-Myers Squibb Company
  • 12.4.1 Bristol-Myers Squibb Company Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Hematologic Malignancies Introduction
  • 12.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.4.5 Bristol-Myers Squibb Company Recent Development
• 12.5 AbbVie, Inc.
  • 12.5.1 AbbVie, Inc. Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Hematologic Malignancies Introduction
  • 12.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.5.5 AbbVie, Inc. Recent Development
• 12.6 Novartis AG
  • 12.6.1 Novartis AG Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Hematologic Malignancies Introduction
  • 12.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.6.5 Novartis AG Recent Development
• 12.7 GlaxoSmithKline PLC
  • 12.7.1 GlaxoSmithKline PLC Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Hematologic Malignancies Introduction
  • 12.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.7.5 GlaxoSmithKline PLC Recent Development
• 12.8 Celgene Corporation
  • 12.8.1 Celgene Corporation Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Hematologic Malignancies Introduction
  • 12.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.8.5 Celgene Corporation Recent Development
• 12.9 Johnson & Johnson Services, Inc.
  • 12.9.1 Johnson & Johnson Services, Inc. Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Hematologic Malignancies Introduction
  • 12.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.9.5 Johnson & Johnson Services, Inc. Recent Development
• 12.10 Takeda Pharmaceutical Company limited
  • 12.10.1 Takeda Pharmaceutical Company limited Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Hematologic Malignancies Introduction
  • 12.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2014-2019)
  • 12.10.5 Takeda Pharmaceutical Company limited Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer